Drug Profile

TOL 2

Alternative Names: TOL-2

Latest Information Update: 22 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Toleranzia
Developer Flerie
Class Proteins
Mechanism of Action Acetylcholine inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myasthenia gravis
New Molecular Entity Yes

Highest Development Phases

Preclinical Myasthenia gravis

Most Recent Events

28 Oct 2022 Toleranzia has patents pending for TOL 2 manufacturing method
28 Mar 2022 Toleranzia plans a first-in-human phase I/IIa trial for Myasthenia gravis in Sweden (PO), in the second half of 2023
11 Nov 2021 Preclinical development in Myasthenia gravis is ongoing in Sweden (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com